Development of Genetically Recombinant Rabies Vaccine
- *Corresponding Author:
- Dr. Muhammad Saleem Haider
Professor & Director, Institute of Agricultural Sciences
Punjab University, Quaid-i-Azam Campus
Tel: (O) 00924299231847
Fax: (O) 00924299231847
E-mail: [email protected]
Received Date: October 16, 2012; Accepted Date: October 27, 2012; Published Date: October 31, 2012
Citation: Hussain Z, Haider MS, Ehsan Qureshi ZU, Velasco-Villa A, Afzaal S, et al. (2012) Development of Genetically Recombinant Rabies Vaccine. J Antivir Antiretrovir S15. doi: 10.4172/jaa.S15-003
Copyright: © 2012 Hussain Z, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Purpose: Pakistan is one of the few countries where Rabies is endemic and a great threat to humans as well as live stocks. A large number of individuals died of rabies exposure due to either the limited access to rabies vaccines or the side-effects of sheep brain -originated Sample vaccine. Cell culture-derived rabies vaccines are mostly unaffordable to the needed population under rabies threat. Development of a safer and more affordable vaccine is necessary in Pakistan. Here, we developed two novel recombinant rabies virus vaccines using a local Pakistan rabies virus glycoprotein gene, and tested the efficacy of vaccines in mice.
Methods: The glycoprotein gene (RVG) of vector ERAg3p and ERAg3m was substituted, respectively, with a modified Pakistani RVG. The resulting recombinant vectors were applied for reverse genetics to recover two vaccine viruses, PK-SG and PK-DG. The efficacy of PK-SG and PK-DG were tested in mice by intramuscular injection and oral delivery.
Results: All mice survived the challenge after intramuscular vaccination using PK-SG, or PK-DG. In the oral
vaccination groups, 80% mice with PK-SG and 90% mice with PK-DG survived the challenge. Meanwhile, 80% of the unvaccinated control mice succumbed after challenge. The mean rabies virus neutralizing antibody titers was ≥0.5 IU/ml in all vaccinated groups.
Conclusion: Our results demonstrated the efficacy of PK-SG and PK-DG in rabies vaccination in mice. The two recombinant virus strains may be good vaccine candidates for the target animals and humans in Pakistan. Detailed investigations are necessary in the future.